These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 18388929)

  • 1. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia.
    Nikol S; Baumgartner I; Van Belle E; Diehm C; Visoná A; Capogrossi MC; Ferreira-Maldent N; Gallino A; Wyatt MG; Wijesinghe LD; Fusari M; Stephan D; Emmerich J; Pompilio G; Vermassen F; Pham E; Grek V; Coleman M; Meyer F;
    Mol Ther; 2008 May; 16(5):972-8. PubMed ID: 18388929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Angiogenesis With Intramuscular NV1FGF Improves Amputation-free Survival in Patients With Critical Limb Ischemia.
    Nikol S; Baumgartner I; Van Belle E; Diehm C; Visoná A; Capogrossi MC; Ferreira-Maldent N; Gallino A; Graham Wyatt M; Dinesh Wijesinghe L; Fusari M; Stephan D; Emmerich J; Pompilio G; Vermassen F; Pham E; Grek V; Coleman M; Meyer F
    Mol Ther; 2008 May; 16(5):972-978. PubMed ID: 28178491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia.
    Belch J; Hiatt WR; Baumgartner I; Driver IV; Nikol S; Norgren L; Van Belle E;
    Lancet; 2011 Jun; 377(9781):1929-37. PubMed ID: 21621834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local gene transfer and expression following intramuscular administration of FGF-1 plasmid DNA in patients with critical limb ischemia.
    Baumgartner I; Chronos N; Comerota A; Henry T; Pasquet JP; Finiels F; Caron A; Dedieu JF; Pilsudski R; Delaère P
    Mol Ther; 2009 May; 17(5):914-21. PubMed ID: 19240689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial.
    Comerota AJ; Throm RC; Miller KA; Henry T; Chronos N; Laird J; Sequeira R; Kent CK; Bacchetta M; Goldman C; Salenius JP; Schmieder FA; Pilsudski R
    J Vasc Surg; 2002 May; 35(5):930-6. PubMed ID: 12021709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia.
    Powell RJ; Simons M; Mendelsohn FO; Daniel G; Henry TD; Koga M; Morishita R; Annex BH
    Circulation; 2008 Jul; 118(1):58-65. PubMed ID: 18559703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety of intramuscular gene transfer of non-viral FGF1 for peripheral artery disease.
    Niebuhr A; Henry T; Goldman J; Baumgartner I; van Belle E; Gerss J; Hirsch AT; Nikol S
    Gene Ther; 2012 Mar; 19(3):264-70. PubMed ID: 21716303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NV1FGF, a pCOR plasmid-based angiogenic gene therapy for the treatment of intermittent claudication and critical limb ischemia.
    Maulik N
    Curr Opin Investig Drugs; 2009 Mar; 10(3):259-68. PubMed ID: 19333884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenic gene therapy does not cause retinal pathology.
    Prokosch V; Stupp T; Spaniol K; Pham E; Nikol S
    J Gene Med; 2014; 16(9-10):309-16. PubMed ID: 25322754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic angiogenesis gains a leg to stand on.
    Rück A; Sylvén C
    Mol Ther; 2008 May; 16(5):808-10. PubMed ID: 18432271
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial.
    Powell RJ; Goodney P; Mendelsohn FO; Moen EK; Annex BH;
    J Vasc Surg; 2010 Dec; 52(6):1525-30. PubMed ID: 21146749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SDF-1 plasmid treatment for patients with peripheral artery disease (STOP-PAD): Randomized, double-blind, placebo-controlled clinical trial.
    Shishehbor MH; Rundback J; Bunte M; Hammad TA; Miller L; Patel PD; Sadanandan S; Fitzgerald M; Pastore J; Kashyap V; Henry TD
    Vasc Med; 2019 Jun; 24(3):200-207. PubMed ID: 30786835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes.
    Nehler MR; Brass EP; Anthony R; Dormandy J; Jiao J; McNamara TO; Hiatt WR;
    J Vasc Surg; 2007 May; 45(5):953-60; discussion 960-1. PubMed ID: 17350216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Safety and Preliminary Efficacy of Plasmid pUDK-HGF Expressing Human Hepatocyte Growth Factor (HGF) in Patients with Critical Limb Ischemia.
    Cui S; Guo L; Li X; Gu Y; Fu J; Dong L; Song H; Chen X; Lu Y; Hu C; Xiao F; Zhu D; Wu Z; Zhang Q
    Eur J Vasc Endovasc Surg; 2015 Oct; 50(4):494-501. PubMed ID: 26122834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early results and lessons learned from a multicenter, randomized, double-blind trial of bone marrow aspirate concentrate in critical limb ischemia.
    Iafrati MD; Hallett JW; Geils G; Pearl G; Lumsden A; Peden E; Bandyk D; Vijayaraghava KS; Radhakrishnan R; Ascher E; Hingorani A; Roddy S
    J Vasc Surg; 2011 Dec; 54(6):1650-8. PubMed ID: 22019148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial.
    Kusumanto YH; van Weel V; Mulder NH; Smit AJ; van den Dungen JJ; Hooymans JM; Sluiter WJ; Tio RA; Quax PH; Gans RO; Dullaart RP; Hospers GA
    Hum Gene Ther; 2006 Jun; 17(6):683-91. PubMed ID: 16776576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic angiogenesis using gene transfer and stem cell therapy in peripheral artery disease].
    Nikol S
    Dtsch Med Wochenschr; 2011 Apr; 136(14):672-4. PubMed ID: 21448824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights on the role of diabetes and geographic variation in patients with critical limb ischaemia.
    Van Belle E; Nikol S; Norgren L; Baumgartner I; Driver V; Hiatt WR; Belch J
    Eur J Vasc Endovasc Surg; 2011 Sep; 42(3):365-73. PubMed ID: 21696982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Hepatocyte Growth Factor in the Treatment of Critical Limb Ischemia.
    Gu Y; Cui S; Wang Q; Liu C; Jin B; Guo W; Liu C; Chu T; Shu C; Zhang F; Han C; Liu Y
    Mol Ther; 2019 Dec; 27(12):2158-2165. PubMed ID: 31805256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia.
    Shigematsu H; Yasuda K; Iwai T; Sasajima T; Ishimaru S; Ohashi Y; Yamaguchi T; Ogihara T; Morishita R
    Gene Ther; 2010 Sep; 17(9):1152-61. PubMed ID: 20393508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.